Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Study shows record surge in reduced kidney function worldwide

8

Nov 2025

Study shows record surge in reduced kidney function worldwide

Record numbers of men and women globally are now estimated to have reduced kidney function, a new study shows. Figures rose from 378 million people with the disease in 1990 to 788 million in 2023 as the world population grew and aged, making it for the first time a top 10 cause of death worldwide.

New study reveals CKD affects nearly 800 million adults worldwide

7

Nov 2025

New study reveals CKD affects nearly 800 million adults worldwide

The number of adults living with chronic kidney disease (CKD) has more than doubled since 1990, reaching nearly 800 million worldwide, according to new research published in The Lancet. The findings come from the Global Burden of Disease (GBD) 2023 study, which tracked CKD trends among adults age 20 years and older across 204 countries and territories from 1990 through 2023.

SGLT2 inhibitors show consistent cardio-renal protection in 70,000 patients

7

Nov 2025

SGLT2 inhibitors show consistent cardio-renal protection in 70,000 patients

In late-breaking presentations at the American Society of Nephrology Kidney Week meeting and simultaneously published in two companion papers in JAMA, the findings are based on data from over 70,000 participants across 10 major randomised controlled trials. The meta-analyses were conducted by the SGLT2 Inhibitor Meta-analysis Cardio-Renal Trialists' Consortium (SMART-C), led by The George Institute for Global Health.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.